|Articles|October 1, 2002

October 2002
Volume 8
Issue 10

Growth in Use of Lipid-lowering Therapies: Are We Targeting the Right Patients?

Author(s)Robert W. Dubois, MD, PhD, Charles M. Alexander, MD, Sally W. Wade, MPH

Download PDF: Growth in Use of Lipid-lowering Therapies: Are We Targeting the Right Patients?

Articles in this issue

over 23 years ago

Article

Women's Reports of Smoking Cessation Advice During Reproductive Health Visits and Subsequent Smoking Cessation

over 23 years ago

Article

A Platform for Population-based Weight Management: Description of a Health Plan-based Integrated Systems Approach

over 23 years ago

Article

COX-2-Specific Inhibitors: Prescribing Patterns in a Large Managed Care Health System and Strategies to Minimize Costs

over 23 years ago

Article

Managed Care Plans' Requirements for Screening for Alcohol, Drug, and Mental Health Problems in Primary Care

over 23 years ago

Article

Evolving Dissatisfaction Among Primary Care Physicians

over 23 years ago

Article

Delivery of Ipratropium and Albuterol Combination Therapy for Chronic Obstructive Pulmonary Disease: Effectiveness of a Two-in-one Inhaler Versus Separate Inhalers

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Growth in Use of Lipid-lowering Therapies: Are We Targeting the Right Patients?

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis